Request Deal Involvement

ORI Capital, Longitude Capital and Decheng Capital led a $120m Series E funding round in CG Oncology.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Service Providers

Latham & Watkins

legal advisors

Latham & Watkins

KKH Advisors

pr advisors

KKH Advisors

or

Principals

CG ONCOLOGY

target

CG ONCOLOGY

ALLY BRIDGE GROUP

bidder

ALLY BRIDGE GROUP

MALIN CORPORATION PLC

bidder

MALIN CORPORATION PLC

SIRONA CAPITAL

bidder

SIRONA CAPITAL

ORI CAPITAL

bidder

ORI CAPITAL

LONGITUDE CAPITAL MANAGEMENT CO LLC

bidder

LONGITUDE CAPITAL MANAGEMENT CO LLC

DECHENG CAPITAL LLC

bidder

DECHENG CAPITAL LLC

RA CAPITAL MANAGEMENT

bidder

RA CAPITAL MANAGEMENT

ACORN BIOVENTURES

bidder

ACORN BIOVENTURES

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite

MergerLinks - Request Credit - ORI Capital, Longitude Capital and Decheng Capital led a $120m Series E funding round in CG Oncology.